Past Papers · SAQ
Haemostasis — Tranexamic Acid
2013A Q04
Exam questionDescribe the pharmacology of tranexamic acid.
CICMWrecks answer
Master answer
Canonical sourceCanonical Pharmacopeia entry
Open in PharmacopeiaCWP-0262
TRANEXAMIC ACID
Haematology · Haematology · Level 3
Core pharmacology
- Class Group
AntiFibrinolytic
- Introduction
Synthetic Lysine Derivative Antifibrinolytic
- Indications Uses
1. Trauma
2. Elective Arthroplasty
3. Hemophilia
4. Obstetric surgery
5. Menorrhagia
6. Recent evidence to suggest possible role in mild to moderate TBI- Presentation
PO and IV
500mg tablet, 1g IV- Mechanism of action
Reversibly inhibits lysine binding sites on plasminogen → Inhibits conversion of plasminogen to plasmin, thereby preventing the breakdown of fibrin
- Adverse Effects Toxicity
1. Abdominal pain, especially on rapid bolus
2. Possible risk of increased VTE (exact risk is controversial)
3. Delayed seizures- Absorption
BA 50%
- Protein binding
<3L PB
- Volume of distribution
Vd- 9-12L, crosses into all tissues
- Metabolism
Minimally metabolized
- Excretion
95% unchanged in urine
- Half-life
T1/2 90min-3 hours
Past papers
Exam appearances
| Exam | Exact exam wording | Candidate success |
|---|---|---|
| 2013A Q04 | Describe the pharmacology of tranexamic acid. | — |